-
NHL/ALL immunotherapy candidate dual antibody drug YK012 has officially entered the phase I clinical trial phase
NHL/ALL免疫治疗候选双抗药物YK012 正式进入I期临床试验阶段2023年5月8日，益科思特（北京）医药科技发展有限公司开发的用于治疗复发性/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012（CD3×CD19）I期临床研究在京正式启动。5月9日，首例受试者顺利签署知情同意书。中国医学科学院肿瘤医院临床研究中心副院长、肿瘤内科主任石远凯教授（左2），益科思特（北京）医药科技发
2023/06/07 admin 851
-
Nature Major findings: lower affinity agonist antibody is more effective
Nature重大发现：较低亲和力激动型抗体疗效更优长期以来，研究人员将高亲和力作为筛选治疗性抗体的关键标准。目前研究中的激动型抗体多数具有很高的亲和力，并且通过抗体的Fc功能进行交联，从而激活免疫细胞，但是这些抗体在临床中的疗效甚微，或具有较强的免疫不良反应。近日，Nature期刊上发表了题为“Reducing affinity as a strategy to boost immunomodul
2023/03/02 admin 93
-
Phase I clinical trial project of YK012 for injection was officially launched
After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.YK012 for injection is a new generation of safe, high-yield, long-acting and low-c
2023/02/07 admin 199
-
The 2022 year-end summary meeting ended successfully
On January 18, 2023, the 2022 year-end summary meeting of Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. was held in the A101 conference room. All members of the company and the cha
2023/01/10 admin 52
-
The leaders went to the Sino-Science Life Science Industrial Park for investigation
In the afternoon of November 17, Meng Qingwu, Chairman of Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd., and Qian Min, Chief Operating Officer, led a delegation to visit the Zhong
2022/11/10 admin 44
-
Fight against COVID-19 - EXCYTE is in action
"Great Xia, for the country and the people". In 2022, the epidemic was still raging. In response to the call, Yikester, Fan Shuang, Li Meiling and Wei Kun, three comrades, took the initiat
2022/01/10 admin 47
